Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
Dosages and duration of treatment; incidence of adverse events throughout study. Changes from baseline to end of study in laboratory values, vital signs, electrocardiograms, and AIMS, BARS, and SAS scale scores.
The change from baseline score to end point score at each point of measurement for PANSS, PSP, CGI S, SQLS-R4, and Sleep VAS.
65 Years and older (Adult, Senior)
June 16, 2004
June 8, 2011
† Study has passed its completion date and status has not been verified in more than two years.